AccuraGen Holdings Limited


About Us

Since its inception in 2013, AccuraGen has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment. Our international team of scientists brings together the best of industry with the best of academia. We currently operate from two locations: Menlo Park, California and Shanghai, China.

Management team

Kevin Liu


Director + General Manager of Junson Capital

Director
+ General Manager of Junson Capital

Investors1

Investors1
Investors1

Investors

Thomas Jefferson University Hospital (USA)

Thomas Jefferson University Hospital (USA)
Thomas Jefferson University Hospital (USA)

  • Thomas Jefferson University Hospital (USA)


Changzheng Hospital (China)

Changzheng Hospital (China)
Changzheng Hospital (China)

  • Changzheng Hospital (China)


Washington Univ. School of Medicine & Genome Center (USA)

Washington Univ. School of Medicine & Genome Center (USA)
Washington Univ. School of Medicine & Genome Center (USA)

  • Washington Univ. School of Medicine & Genome Center (USA)


Xinhuan Hospital (China)

Xinhuan Hospital (China)
Xinhuan Hospital (China)

  • Xinhuan Hospital (China)


Stanford School of Medicine (USA)

Stanford School of Medicine (USA)
Stanford School of Medicine (USA)

  • Stanford School of Medicine (USA)


Beijing Cancer Center (China)

Beijing Cancer Center (China)
Beijing Cancer Center (China)

  • Beijing Cancer Center (China)


Changhai Hospital (China)

Changhai Hospital (China)
Changhai Hospital (China)

  • Changhai Hospital (China)


Beijing Meitan Cancer Hospital (China)

Beijing Meitan Cancer Hospital (China)
Beijing Meitan Cancer Hospital (China)

  • Beijing Meitan Cancer Hospital (China)


06/2016 ASCO abstract 4

06/2016 ASCO abstract 4
http://abstract.asco.org/176/AbstView_176_170697.html

06/2016 ASCO abstract 3

06/2016 ASCO abstract 3
http://abstract.asco.org/176/AbstView_176_169790.html

06/2016 ASCO abstract 2

06/2016 ASCO abstract 2
http://abstract.asco.org/176/AbstView_176_169942.html

06/2016 ASCO abstract 1

06/2016 ASCO abstract 1
http://abstract.asco.org/176/AbstView_176_170474.html

6/01/2016 AccuraGen, a US-China Cancer DiagnosticsCompany, Raises $40 Million

6/01/2016 AccuraGen, a US-China Cancer DiagnosticsCompany, Raises $40 Million
http://www.chinabiotoday.com/articles/20160601

4/18/2016 AACR poster

4/18/2016 AACR poster
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=78188e22-2da5-4b5b-a062-580e8614d15e&cKey=4a6384e0-86ac-4152-ae3b-84bb6e2d6ddc&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267

3/10/2016 Circulating Cell-Free DNA symposium - Molecular Med Tri-Con presentation

3/10/2016 Circulating Cell-Free DNA symposium - Molecular Med Tri-Con presentation
https://www.genomeweb.com/sequencing-technology/startup-accuragen-tap-china-liquid-biopsy-market-61-gene-assay

11/7/2015 AACR-NCI-EORTC poster

11/7/2015 AACR-NCI-EORTC poster
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3651&sKey=9f1e9b43-d9db-4e01-abb7-dfd57a0d321f&cKey=eacb85a5-4941-4612-b649-c0e39ed0d940&mKey=c69f0c7b-cff2-4010-ac6c-deae12e60491

4/20/2015 AACR poster

4/20/2015 AACR poster
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3682&sKey=68268ed4-0775-4766-b5c8-814720bdafea&cKey=4bc4501d-323a-4905-bab4-c09daab15048&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424


Dan Zabrowski

Dan Zabrowski
Dan Zabrowski

Independent Director
+ Head of Roche Sequencing and Tissue Diagnostics

Advisor

Cancer-specific MRD

+ Detection of cancer signature mutations from plasma 

Pan-cancer Treatment

+ Supporting target therapy selection

+ Monitoring of drug resistant mutation

Firefly™ Technology

+   Efficient amplification of highly fragmented cfDNA 

+   Best-in-class sensitivity & specificity


Paul Tang

Li Weng

Malek Faham

Kang Ying

co-founder

Richard Myers, PhD

The former director of the Stanford Human Genome Center, Dr. Myers currently serves as the president of the HudsonAlpha Institute for Biotechnology.

David Euhus, MD

Dr. David Euhus is the chief of breast surgery in the Department of Surgical Oncology at Johns Hopkins University.

Kang Ying

MD/PhD/Chairman 

Min Cui

PhD/Director
+ Managing Director of Decheng Capital

Wei Xu

MEC Director
+ Executive Partner of Denlux Capital

Dan Zabrowski

Independent Director
+ Head of Roche Sequencing and Tissue Diagnostics

4/20/2015 AACR poster


11/7/2015 AACR-NCI-EORTC poster

3/10/2016 Circulating Cell-Free DNA symposium - Molecular Med Tri-Con presentation

4/18/2016 AACR poster

6/01/2016 AccuraGen, a US-China Cancer DiagnosticsCompany, Raises $40 Million

06/2016 ASCO abstract 1

06/2016 ASCO abstract 2

Board

Cancer-specific MRD

+ Detection of cancer signature mutations from plasma 

Pan-cancer Treatment

+ Supporting target therapy selection

+ Monitoring of drug resistant mutation

Firefly™ Technology

+   Efficient amplification of highly fragmented cfDNA 

+   Best-in-class sensitivity & specificity


Paul Tang

Li Weng

Malek Faham

Kang Ying

co-founder

Richard Myers, PhD

The former director of the Stanford Human Genome Center, Dr. Myers currently serves as the president of the HudsonAlpha Institute for Biotechnology.

David Euhus, MD

Dr. David Euhus is the chief of breast surgery in the Department of Surgical Oncology at Johns Hopkins University.

Kang Ying

MD/PhD/Chairman 

Min Cui

PhD/Director
+ Managing Director of Decheng Capital

Wei Xu

MEC Director
+ Executive Partner of Denlux Capital

Dan Zabrowski

Independent Director
+ Head of Roche Sequencing and Tissue Diagnostics

4/20/2015 AACR poster


11/7/2015 AACR-NCI-EORTC poster

3/10/2016 Circulating Cell-Free DNA symposium - Molecular Med Tri-Con presentation

4/18/2016 AACR poster

6/01/2016 AccuraGen, a US-China Cancer DiagnosticsCompany, Raises $40 Million

06/2016 ASCO abstract 1

06/2016 ASCO abstract 2

Investors